Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Mellinghoff
Ingo Mellinghoff, MD, is an oncologist based in New York, NY. He completed an Internal Medicine Residency and Hematology/Oncology Fellowship at the University of California Los Angeles Medical Center. He is currently Attending Physician and Department Chair at Memorial Sloan Kettering Cancer Center. He is an elected member of the Association of American Physicians and the American Society of Clinical Investigation.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2004- UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Internal Medicine, 1998 - 1999
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1995 - 1998
Technical University Munich Faculty of MedicineClass of 1993
Certifications & Licensure
CA State Medical License 1997 - 2027
NY State Medical License 2008 - 2027
NH State Medical License 2024 - 2026
Awards, Honors, & Recognition
- Member (elected) Association of American Physicians, 2020
- Member (elected) American Society of Clinical Investigation, 2013
Clinical Trials
- EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas Start of enrollment: 2011 Jan 07
- Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- 6 citationsImmune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors.Andrew L Lin, Vasilisa Rudneva, Adam Newton, Nazanin K Majd, Rajiv Magge
The Journal of Clinical Endocrinology and Metabolism. 2025-10-16 - F-BMS-986229 PET imaging of tumor PD-L1 expression in glioblastoma patients.Milan Grkovski, Mariza Daras, Tejus Bale, Serge Lyashchenko, Anne S Reiner
EJNMMI Research. 2025-09-26 - Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma.Lauren R Schaff, Anna F Piotrowski, Elena Pentsova, Igor T Gavrilovic, Andrew Lin
Neuro-Oncology. 2025-09-17
Abstracts/Posters
- Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)Ingo K Mellinghoff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1.2019 ASCO Annual Meeting - 6/1/2019
- Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Press Mentions
IDH Inhibitor Activity in Brain Cancer Persists with Longer Follow-UpNovember 24th, 2024- Health Canada Approves First and Only Oral Treatment for Brain CancerOctober 22nd, 2024
- May 2024 Neurology Recall: Topics in Neuro-OncologyMay 1st, 2024
- Join now to see all
Grant Support
- Molecular Mechanisms of Drug Resistance in Primary Brain TumorsSLOAN-KETTERING INST CAN RESEARCH2018–2025
Professional Memberships
- Member
- American Association for Cancer Research - AACRMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
